Biotek-snakken — December 2020
-
"In fact this molecule is going to go into Phase III first-line and they're working with a Chinese company called BeiGene. So BeiGene is partnering with Zymeworks. In terms of the trial design it should be compared to Herceptin plus chemotherapy versus zanidatamab plus chemotherapy. And that will be a third arm, which will be zanidatamab and BeiGene's own PD-1 inhibitor, tislelizumab and chemotherapy.
-
Paa Placeras Immunovia forum skriver de at denne artikel er skylden: https://www.di.se/live/diagnostikbolagets-aktie-pressas-efter-di-s-granskning/
-
Nej, den kender jeg ikke - er du i begge aktier? Er vel vanskeligt at regne "fair value" på den type selskaber....som så mange af de andre aktier vi kigger på
Men jeg synes kursudvikling og volume i dag er mystisk, og jeg kan ikke finde nyheder som understøtter!? -
-
Video fra ØU med Hansa Biopharma: https://vimeo.com
/483997561?mc_eid=513463285b&mc_cid=87d7874648
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind